Switch theme
Sign up to access all valuation multiples
Alliance Pharma PLC is a player in the healthcare market. The company's business includes the acquisition, marketing, and distribution of consumer healthcare and pharmaceutical products. The group operates in two segments: Consumer Healthcare brands and Prescription Medicines. The company generates the majority of its revenue from the Consumer Healthcare segment. The products of the company include Aloclair, Biodermatin, Changmin, Decapional, Effadiane, Fazol, and others. Geographically, the company derives a majority of its revenue from Europe, the Middle East, and Africa (EMEA).
2001
292
LTM Revenue $238M
LTM EBITDA $56.9M
$528M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Alliance Pharma has a last 12-month revenue of $238M and a last 12-month EBITDA of $56.9M.
In the most recent fiscal year, Alliance Pharma achieved revenue of $230M and an EBITDA of $5.0M.
Alliance Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Alliance Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $233M | $230M | XXX | XXX | XXX |
| Gross Profit | $131M | $135M | XXX | XXX | XXX |
| Gross Margin | 56% | 59% | XXX | XXX | XXX |
| EBITDA | -$37.3M | $5.0M | XXX | XXX | XXX |
| EBITDA Margin | -16% | 2% | XXX | XXX | XXX |
| Net Profit | $1.2M | -$42.7M | XXX | XXX | XXX |
| Net Margin | 1% | -19% | XXX | XXX | XXX |
| Net Debt | $131M | $117M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Alliance Pharma's stock price is GBP 1 (or $1).
Alliance Pharma has current market cap of GBP 347M (or $447M), and EV of GBP 410M (or $528M).
See Alliance Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $528M | $447M | XXX | XXX | XXX | XXX | $0.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Alliance Pharma has market cap of $447M and EV of $528M.
Alliance Pharma's trades at 2.2x LTM EV/Revenue multiple, and 9.3x LTM EBITDA.
Analysts estimate Alliance Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Alliance Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $528M | XXX | XXX | XXX |
| EV/Revenue | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | 106.2x | XXX | XXX | XXX |
| P/E | -32.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 10.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAlliance Pharma's NTM/LTM revenue growth is 10%
Alliance Pharma's revenue per employee for the last fiscal year averaged $0.8M, while opex per employee averaged $0.4M for the same period.
Over next 12 months, Alliance Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Alliance Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Alliance Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -1% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 2% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -113% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 12% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.8M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 40% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 45% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alliance Pharma acquired XXX companies to date.
Last acquisition by Alliance Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Alliance Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Alliance Pharma founded? | Alliance Pharma was founded in 2001. |
| Where is Alliance Pharma headquartered? | Alliance Pharma is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does Alliance Pharma have? | As of today, Alliance Pharma has 292 employees. |
| Who is the CEO of Alliance Pharma? | Alliance Pharma's CEO is Mr. Nicholas John Sedgwick. |
| Is Alliance Pharma publicy listed? | Yes, Alliance Pharma is a public company listed on LON. |
| What is the stock symbol of Alliance Pharma? | Alliance Pharma trades under APH ticker. |
| When did Alliance Pharma go public? | Alliance Pharma went public in 2001. |
| Who are competitors of Alliance Pharma? | Similar companies to Alliance Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Alliance Pharma? | Alliance Pharma's current market cap is $447M |
| What is the current revenue of Alliance Pharma? | Alliance Pharma's last 12-month revenue is $238M. |
| What is the current EBITDA of Alliance Pharma? | Alliance Pharma's last 12-month EBITDA is $56.9M. |
| What is the current EV/Revenue multiple of Alliance Pharma? | Current revenue multiple of Alliance Pharma is 2.2x. |
| What is the current EV/EBITDA multiple of Alliance Pharma? | Current EBITDA multiple of Alliance Pharma is 9.3x. |
| What is the current revenue growth of Alliance Pharma? | Alliance Pharma revenue growth between 2023 and 2024 was -1%. |
| Is Alliance Pharma profitable? | Yes, Alliance Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
